Skip to main content

Cystaran FDA Approval History

FDA Approved: Yes (First approved October 2, 2012)
Brand name: Cystaran
Generic name: cysteamine hydrochloride
Dosage form: Ophthalmic Solution
Company: Sigma-Tau Pharmaceuticals, Inc.
Treatment for: Cystinosis

Cystaran (cysteamine cysteamine ophthalmic solution) is a cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis.

Development timeline for Cystaran

DateArticle
Oct  9, 2012Approval Sigma-Tau Pharmaceuticals, Inc. Receives FDA Approval of Cystaran (cysteamine ophthalmic solution) 0.44%
May 17, 2010Sigma-Tau Pharmaceuticals Cysteamine Eye Drop NDA Accepted for Filing

See also

Cystaran (cysteamine hydrochloride) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer